Latest Research Progress of E3 Ubiquitin Ligase in the Diagnosis and Treatment of Acute Myeloid Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2025.05.045
- Author:
Wei-Lin LIU
1
;
Chun-Yi LYU
1
;
Teng WANG
1
;
Chen HAN
1
;
Rui-Rong XU
2
Author Information
1. The First clinical medical School, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China.
2. Key Laboratory of Hematology of Integrated Traditional Chinese and Western Medicine of Health Commission of Shandong Province, Institute of Hematology of Shandong University of Traditional Chinese, Department of Hematology of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China.
- Publication Type:English Abstract
- Keywords:
acute myeloid leukemia；E3 ubiquitin ligase；targeted therapy；immune response
- MeSH:
Humans;
Ubiquitin-Protein Ligases/metabolism*;
Leukemia, Myeloid, Acute/therapy*
- From:
Journal of Experimental Hematology
2025;33(5):1542-1545
- CountryChina
- Language:Chinese
-
Abstract:
E3 ubiquitin ligase is a key enzyme that determines substrate specificity during ubiquitination and plays an important role in regulating the degradation of tumor suppressor or oncogenic proteins. E3 ubiquitin ligase is involved in regulating leukemia cell differentiation, cell cycle and immune response, and it is closely related to the occurrence and development of acute myeloid leukemia (AML). Targeting highly specific E3 ubiquitin ligase can be used as an effective treatment for AML. This article reviewed the latest progress of E3 ubiquitin ligase in the diagnosis and treatment of AML, aiming to provide insights for the precise targeted therapy of this disease.
